Search results

635 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
Research recommendations Remove Research recommendations filter
In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Social care guidelines Remove Social care guidelines filter

Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

In development [GID-TA10570] Expected publication date: 17 November 2021

Type

Technology appraisal guidance

Status

In development
Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

In development [GID-TA10387] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously treated EGFR-positive metastatic non-small-cell lung cancer [ID3873]

Proposed [GID-TA10766] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]

Proposed [GID-TA10767] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]

Proposed [GID-TA10768] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]

Proposed [GID-TA10770] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tofacitinib for treating active ankylosing spondylitis [ID3865]

Proposed [GID-TA10771] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Foscarbidopa–foslevodopa for treating motor fluctuations in Parkinson's disease [ID3876]

Proposed [GID-TA10772] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

Proposed [GID-TA10773] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

Proposed [GID-TA10774] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]

Proposed [GID-TA10775] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Andexanet alfa for reversing anticoagulation [ID1101]

In development [GID-TA10440] Expected publication date: 14 April 2021

Type

Technology appraisal guidance

Status

In development
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]

Proposed [GID-TA10776] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]

Proposed [GID-TA10777] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]

Proposed [GID-TA10778] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

Proposed [GID-TA10779] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Midostaurin for treating advanced systemic mastocytosis ID1573

In development [GID-TA10503] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]

In development [GID-TA10526] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
V.A.C. VERAFLO Therapy System for acute infected or chronic wounds that are failing to heal (MT471)

In development [GID-MT543] Expected publication date: 27 January 2020

Type

Medical technologies guidance

Status

In development
Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]

In development [GID-TA10693] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lenvatinib with pembrolizumab for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811]

In development [GID-TA10692] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

Proposed [GID-TA10715] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]

Proposed [GID-TA10717] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]

Proposed [GID-TA10718] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]

Proposed [GID-TA10719] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lifitegrast for treating dry eye disease [ID1229]

In development [GID-TA10196] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Abicipar pegol for treating wet age-related macular degeneration ID1533

In development [GID-TA10511] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]

In development [GID-TA10442] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Melanoma (metastatic) - talimogene laherparepvec [ID508]

In development [GID-TAG509] Expected publication date: 28 September 2016

Type

Technology appraisal guidance

Status

In development
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]

In development [GID-TA10026] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Proposed [GID-TA10198] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Proposed [GID-TA10336] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)

Proposed [GID-TA10426] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Psoriasis - briakinumab (suspended) [ID65]

In development [GID-TAG412] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Voxelotor for treating sickle cell disease [ID1403]

Proposed [GID-TA10505] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Semaglutide for treating type 2 diabetes (ID1450)

Proposed [GID-TA10438] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

Proposed [GID-TA10297] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pegvaliase for treating phenylketonuria [ID1110]

Proposed [GID-TA10345] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)

Proposed [GID-TA10239] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Rivaroxaban for treating chronic heart failure [ID1462]

Proposed [GID-TA10393] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Osteoarthritis - naproxcinod [ID417]

In development [GID-TAG426] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]

In development [GID-TAG418] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

In development [GID-TAG456] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (acute lymphoblastic) - dasatinib [ID386]

In development [GID-TAG399] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Renal cell carcinoma (second line metastatic) - pazopanib [ID70]

In development [GID-TAG398] Expected publication date: 01 January 2011

Type

Technology appraisal guidance

Status

In development
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

In development [GID-TAG414] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Diabetic foot ulcers - new treatments [ID381]

In development [GID-TAG371] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous leg ulcers - new treatments [ID394]

In development [GID-TAG370] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous thromboembolism (VTE) - ximelagatran [ID396]

In development [GID-TAG378] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development